Prime Medicine, Inc.

Contributing Author

Recent Articles by Prime Medicine, Inc.

Nov-12	Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares PRME -9.53% GlobeNewswire
Nov-12	Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates PRME -9.53% GlobeNewswire
Nov-10	Prime Medicine Announces Pricing of Public Offering of Common Stock PRME +10.26% GlobeNewswire
Nov-10	Prime Medicine Announces Proposed $125.0 Million Public Offering of Common Stock PRME -9.30% PRME +10.26% GlobeNewswire
Nov-09	Prime Medicine to Present at Jefferies Global Healthcare Conference PRME -7.53% GlobeNewswire
Oct-05	Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease PRME +7.72% GlobeNewswire
Sep-24	Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency PRME PRME -5.54% GlobeNewswire
Aug-06	Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates PRME GlobeNewswire
Jul-23	Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease PRME GlobeNewswire
Jul-08	Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics PRME +15.79% GlobeNewswire
Jun-22	Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD) PRME GlobeNewswire
Jun-18	Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease PRME GlobeNewswire
Jun-03	Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference PRME GlobeNewswire
May-28	Prime Medicine to Present at Jefferies Global Healthcare Conference PRME GlobeNewswire
May-07	Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates PRME -8.65% GlobeNewswire
Apr-16	Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer PRME GlobeNewswire
Mar-03	Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates PRME -9.23% GlobeNewswire
Feb-25	Prime Medicine to Participate in Upcoming Investor Conferences PRME +7.83% GlobeNewswire
Jan-07	Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference PRME +9.19% GlobeNewswire
Dec-07	Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease PRME GlobeNewswire
Nov-25	Prime Medicine to Present at 8th Annual Evercore Healthcare Conference PRME GlobeNewswire
Nov-11	Prime Medicine to Present at Jefferies Global Healthcare Conference PRME +11.21% GlobeNewswire
Nov-07	CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates PRME -8.85% GlobeNewswire
Nov-07	Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates PRME -8.85% GlobeNewswire
Nov-03	Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer PRME -7.69% GlobeNewswire
Oct-30	Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy PRME PRME +13.56% GlobeNewswire
Oct-07	Prime Medicine to Participate in Upcoming Investor Conferences PRME GlobeNewswire
Aug-26	Prime Medicine to Participate in Upcoming Investor Conferences PRME GlobeNewswire
Aug-07	Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates PRME -9.58% GlobeNewswire
Aug-01	Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares PRME +8.02% PRME +11.39% GlobeNewswire
Jul-30	Prime Medicine Announces Pricing of Public Offering PRME GlobeNewswire
Jul-30	Prime Medicine Announces Proposed Public Offering of Common Stock PRME GlobeNewswire
Jul-16	Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis PRME -5.83% GlobeNewswire
May-29	Prime Medicine to Participate in Upcoming Investor Conferences PRME GlobeNewswire
May-19	Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition PRME -16.04% GlobeNewswire
May-19	Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease PRME -16.04% GlobeNewswire
May-08	Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates PRME -7.04% GlobeNewswire

Prime Medicine, Inc.

Recent Articles by Prime Medicine, Inc.

Upgrade your Finviz experience